Generalized Myasthenia Gravis

Immunology·MeSH: Myasthenia Gravis

Prevalence

20.0 / 100K

Incidence

1.7 / 100K/yr

20 drugs in development·11 companies·23 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
Ultomiris	Xencor Inc (XNCR)

Phase 3(6)

Phase 2(5)

Drug	Company
IMVT-1402	Immunovant, Inc. (IMVT)
iptacopan	Novartis AG (NVS)
m281	MOMENTA PHARMACEUTICALS INC (MNTA)
rese-cel	Cabaletta Bio, Inc. (CABA)
rozanolixizumab	GT Biopharma, Inc. (GTBP)

Phase 1(2)

Drug	Company
CABA-201	Filana Therapeutics Inc. (FLNA)
rese-cel (resecabtagene autoleucel)	Cabaletta Bio, Inc. (CABA)

Phase 1/Phase 2(2)

Drug	Company
ytb323	Novartis AG (NVS)
YTB323	Novartis AG (NVS)

Phase 2/Phase 3(2)

Drug	Company
CABA-201	Cabaletta Bio, Inc. (CABA)
zilucoplan	POINT Biopharma Global Inc. (PNT)

Phase 4(2)

Drug	Company
Efgartigimod PH20 SC	ARGENX SE (ARGX)
ravulizumab	ALEXION PHARMACEUTICALS, INC. (ALXN)

BioSniper tracks 20 drugs in development for Generalized Myasthenia Gravis across 11 companies.

There are 23 clinical trials targeting Generalized Myasthenia Gravis tracked by BioSniper.

The estimated prevalence of Generalized Myasthenia Gravis is approximately 20.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.